All News

Found 237 articles

• Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA Conference

  5/8/2023

  Scholar Rock announced today it will present extension data from the Phase 2 TOPAZ trial evaluating patient outcomes after 36 months of treatment with apitegromab.

• Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors

  5/3/2023

  Convergent Therapeutics Inc. today announced the completion of a $90 million Series A financing, led by OrbiMed and RA Capital Management with participation from Invus.

• Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 12, 2023

  4/12/2023

  Scholar Rock today announced that the Company granted inducement equity awards covering an aggregate of 83,125 shares of its common stock to five newly hired employees, consisting of inducement stock options to purchase an aggregate of 47,500 shares of common stock.

• Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  3/15/2023

  Scholar Rock today announced that the company granted inducement equity awards covering an aggregate of 26,250 shares of its common stock to 1 newly hired employee, consisting of inducement stock options to purchase an aggregate of 15,000 shares of common stock.

• Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress

  3/7/2023

  Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2022.

• Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

  3/1/2023

  Scholar Rock today announced it will present data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24 months of treatment with apitegromab.

• CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies

  3/1/2023

  CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced the close of a $200 million oversubscribed and upsized Series A financing.

• Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference

  2/27/2023

  Scholar Rock today announced that management will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 12:50 p.m. ET.

• Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 17, 2023

  2/17/2023

  Scholar Rock announced that the Company granted inducement equity awards covering an aggregate of 285,000 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 255,000 shares of common stock and inducement restricted stock units, covering an aggregate of 30,000 shares of its common stock.

• Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

  2/6/2023

  Scholar Rock today announced the appointment of Tracey M. Sacco as Chief Commercial Officer.

• Adimab Provides 2022 Update on Clinical Pipeline

  1/11/2023

  Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that seven new partner programs entered clinical development in 2022, including programs by Biotheus, Dragonfly, Innovent, Surface Oncology, and a program with financial support from the Gates Foundation.

• 

  JPM Day 2: Highlights

  1/10/2023

  Stay on top of what's happening at JPM. BioSpace is covering all the key announcements all week.

• Adimab Provides Year-End Update on 2022 Partnership Activities

  1/10/2023

  Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it entered into partnership agreements with 11 new companies in 2022.

• Scholar Rock Provides Corporate Update and Highlights Priorities for 2023

  1/9/2023

  Scholar Rock today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2023.

• Exo Therapeutics Appoints Nagesh Mahanthappa as Executive Chair

  1/4/2023

  Exo Therapeutics, Inc. today announced the appointment of Nagesh Mahanthappa, PhD, to Executive Chair.

• Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Scholar Rock today announced that management will present at the J.P. Morgan 41st Annual Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. PT (4:30 p.m. ET).

• Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  11/15/2022

  Scholar Rock today announced that the company granted equity awards as a material inducement to an employee hired by Scholar Rock in November 2022.

• Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress

  11/14/2022

  Scholar Rock today reported financial results and corporate updates for the third quarter ended September 30, 2022.

• Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy

  11/10/2022

  Scholar Rock today announced early data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFβ1 activation being developed with the aim of overcoming resistance to checkpoint therapy in patients with advanced cancer.

• Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer

  11/9/2022

  Scholar Rock today announced the appointment of Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer.